TScan Therapeutics Inc
TCRX0.896USD
-0.035-3.79%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
50.83MMarket Cap
LossP/E TTM
More Details of TScan Therapeutics Inc Company
TScan Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation. The Company is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The Company has developed and continues to build its ImmunoBank with TCRs across different targets and human leukocyte antigens types to enable customized multiplex TCR-T therapy. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204. Its hematologic malignancies programs include TSC-100, TSC-101, and TSC-102.
TScan Therapeutics Inc Info
Ticker SymbolTCRX
Company nameTScan Therapeutics Inc
IPO dateJul 16, 2021
CEOMacbeath (Gavin)
Number of employees194
Security typeOrdinary Share
Fiscal year-endJul 16
Address830 Winter Street
CityWALTHAM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02451
Phone18573999500
Websitehttps://www.tscan.com
Ticker SymbolTCRX
IPO dateJul 16, 2021
CEOMacbeath (Gavin)
Company Executives of TScan Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Zoran Zdraveski, J.D., Ph.D.
Dr. Zoran Zdraveski, J.D., Ph.D.
Chief Legal and Strategy Officer, Secretary
Chief Legal and Strategy Officer, Secretary
84.61K
+1694.13%
Mr. Gavin Macbeath, Ph.D.
Mr. Gavin Macbeath, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
49.77K
--
Mr. Garry A. Nicholson
Mr. Garry A. Nicholson
Independent Director
Independent Director
--
--
Mr. R. Keith Woods
Mr. R. Keith Woods
Independent Director
Independent Director
--
--
Dr. Stephen R. Biggar, M.D., Ph.D.
Dr. Stephen R. Biggar, M.D., Ph.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
Jason A. Amello ,
Jason A. Amello ,
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Dr. Chrystal U. Louis
Dr. Chrystal U. Louis
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Katina Dorton
Ms. Katina Dorton
Independent Director
Independent Director
--
--
Dr. Barbara J. Klencke, M.D.
Dr. Barbara J. Klencke, M.D.
Independent Director
Independent Director
--
--
Dr. Gabriela Gruia, M.D.
Dr. Gabriela Gruia, M.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Zoran Zdraveski, J.D., Ph.D.
Dr. Zoran Zdraveski, J.D., Ph.D.
Chief Legal and Strategy Officer, Secretary
Chief Legal and Strategy Officer, Secretary
84.61K
+1694.13%
Mr. Gavin Macbeath, Ph.D.
Mr. Gavin Macbeath, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
49.77K
--
Mr. Garry A. Nicholson
Mr. Garry A. Nicholson
Independent Director
Independent Director
--
--
Mr. R. Keith Woods
Mr. R. Keith Woods
Independent Director
Independent Director
--
--
Dr. Stephen R. Biggar, M.D., Ph.D.
Dr. Stephen R. Biggar, M.D., Ph.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
Jason A. Amello ,
Jason A. Amello ,
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Revenue Breakdown
FY2025Q2
FY2025Q1
FY2024
FY2023
FY2022
FY2021
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
3.08M
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Dec 4
Updated: Thu, Dec 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Lynx1 Capital Advisors LLC
14.97%
BVF Partners L.P.
9.96%
K2 HealthVentures LLC
6.87%
Simplify Asset Management Inc
5.41%
Baker Bros. Advisors LP
5.31%
Other
57.48%
Shareholders
Shareholders
Proportion
Lynx1 Capital Advisors LLC
14.97%
BVF Partners L.P.
9.96%
K2 HealthVentures LLC
6.87%
Simplify Asset Management Inc
5.41%
Baker Bros. Advisors LP
5.31%
Other
57.48%
Shareholder Types
Shareholders
Proportion
Investment Advisor
29.70%
Hedge Fund
21.44%
Venture Capital
11.33%
Investment Advisor/Hedge Fund
7.88%
Research Firm
2.72%
Individual Investor
0.39%
Bank and Trust
0.27%
Other
26.27%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
198
42.06M
80.16%
-7.95M
2025Q2
192
48.33M
92.38%
-952.90K
2025Q1
198
46.53M
88.95%
-3.07M
2024Q4
184
47.92M
91.75%
+202.11K
2024Q3
172
45.30M
92.65%
-3.14M
2024Q2
147
48.79M
100.07%
+12.56M
2024Q1
110
39.09M
88.67%
+3.45M
2023Q4
95
36.63M
84.04%
+3.23M
2023Q3
84
33.69M
84.61%
-2.13M
2023Q2
78
32.77M
82.58%
-787.78K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Lynx1 Capital Advisors LLC
7.86M
14.97%
-88.79K
-1.12%
Jun 30, 2025
BVF Partners L.P.
5.23M
9.96%
+336.60K
+6.88%
Jun 30, 2025
K2 HealthVentures LLC
3.60M
6.87%
+2.90M
+414.67%
Dec 31, 2024
Simplify Asset Management Inc
1.05M
2%
--
--
Jun 30, 2025
Baker Bros. Advisors LP
2.78M
5.31%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
2.15M
4.1%
-207.37K
-8.80%
Jun 30, 2025
abrdn Inc.
891.45K
1.7%
--
--
Jun 30, 2025
BlackRock Financial Management, Inc.
1.32M
2.51%
-529.55K
-28.71%
Jun 30, 2025
Bessemer Venture Partners
1.25M
2.37%
--
--
Jun 30, 2025
Alphabet, Inc.
1.08M
2.05%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Simplify Propel Opportunities ETF
1.72%
iShares Health Innovation Active ETF
0.13%
iShares Micro-Cap ETF
0.02%
iShares Biotechnology ETF
0.01%
Invesco Nasdaq Biotechnology ETF
0.01%
ProShares Ultra Nasdaq Biotechnology
0.01%
Invesco Dorsey Wright SmallCap Momentum ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
DFA Dimensional US Core Equity Market ETF
0%
iShares Russell 3000 ETF
0%
View more
Simplify Propel Opportunities ETF
Proportion1.72%
iShares Health Innovation Active ETF
Proportion0.13%
iShares Micro-Cap ETF
Proportion0.02%
iShares Biotechnology ETF
Proportion0.01%
Invesco Nasdaq Biotechnology ETF
Proportion0.01%
ProShares Ultra Nasdaq Biotechnology
Proportion0.01%
Invesco Dorsey Wright SmallCap Momentum ETF
Proportion0%
DFA Dimensional US Sustainability Core 1 ETF
Proportion0%
DFA Dimensional US Core Equity Market ETF
Proportion0%
iShares Russell 3000 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of TScan Therapeutics Inc?
The top five shareholders of TScan Therapeutics Inc are:
Lynx1 Capital Advisors LLC holds 7.86M shares, accounting for 14.97% of the total shares.
BVF Partners L.P. holds 5.23M shares, accounting for 9.96% of the total shares.
K2 HealthVentures LLC holds 3.60M shares, accounting for 6.87% of the total shares.
Simplify Asset Management Inc holds 1.05M shares, accounting for 2.00% of the total shares.
Baker Bros. Advisors LP holds 2.78M shares, accounting for 5.31% of the total shares.
Lynx1 Capital Advisors LLC holds 7.86M shares, accounting for 14.97% of the total shares.
BVF Partners L.P. holds 5.23M shares, accounting for 9.96% of the total shares.
K2 HealthVentures LLC holds 3.60M shares, accounting for 6.87% of the total shares.
Simplify Asset Management Inc holds 1.05M shares, accounting for 2.00% of the total shares.
Baker Bros. Advisors LP holds 2.78M shares, accounting for 5.31% of the total shares.
What are the top three shareholder types of TScan Therapeutics Inc?
The top three shareholder types of TScan Therapeutics Inc are:
Lynx1 Capital Advisors LLC
BVF Partners L.P.
K2 HealthVentures LLC
Lynx1 Capital Advisors LLC
BVF Partners L.P.
K2 HealthVentures LLC
How many institutions hold shares of TScan Therapeutics Inc (TCRX)?
As of 2025Q3, 198 institutions hold shares of TScan Therapeutics Inc, with a combined market value of approximately 42.06M, accounting for 80.16% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -12.22%.
What is the biggest source of revenue for TScan Therapeutics Inc?
In FY2025Q2, the -- business generated the highest revenue for TScan Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
